262 related articles for article (PubMed ID: 17954698)
1. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS
Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
[TBL] [Abstract][Full Text] [Related]
3. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
Noel GJ
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
[TBL] [Abstract][Full Text] [Related]
4. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Overcash JS; Kim C; Keech R; Gumenchuk I; Ninov B; Gonzalez-Rojas Y; Waters M; Simeonov S; Engelhardt M; Saulay M; Ionescu D; Smart JI; Jones ME; Hamed KA
Clin Infect Dis; 2021 Oct; 73(7):e1507-e1517. PubMed ID: 32897367
[TBL] [Abstract][Full Text] [Related]
6. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
7. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
Deresinski SC
Diagn Microbiol Infect Dis; 2008 May; 61(1):103-9. PubMed ID: 18384998
[TBL] [Abstract][Full Text] [Related]
9. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
Schirmer PL; Deresinski SC
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220
[TBL] [Abstract][Full Text] [Related]
10. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
11. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
12. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
Stryjewski ME; Potgieter PD; Li YP; Barriere SL; Churukian A; Kingsley J; Corey GR;
Antimicrob Agents Chemother; 2012 Nov; 56(11):5476-83. PubMed ID: 22869571
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
[TBL] [Abstract][Full Text] [Related]
14. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
[TBL] [Abstract][Full Text] [Related]
16. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
17. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
Prokocimer P; Bien P; Surber J; Mehra P; DeAnda C; Bulitta JB; Corey GR
Antimicrob Agents Chemother; 2011 Feb; 55(2):583-92. PubMed ID: 21115795
[TBL] [Abstract][Full Text] [Related]
18. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
19. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
[TBL] [Abstract][Full Text] [Related]
20. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
